Billets de Michelle Dawson

Billet publié sur Bluesky le 15/06/2026 10:53

Bluesky Registre de revue systématique crd.york.ac.uk Extrait cité dans le billet Lien intégré au billet Termes sur l’autisme

Registered: "Adverse events, adverse effects, and harms are important to monitor in autism intervention research. However, little is known about trends in monitoring over time, and the quality of protocols for doing so..." www.crd.york.ac.uk/PROSPERO/vie... systematic review

Voir sur Bluesky

Liens cités structurés

1 ressource citée

Registre de revue systématique Récupéré Publication crd.york.ac.uk

Kristen Bottema-Beutel, Micheal Sandbank, Tiffany Woynaroski, Jacob Feldman, Shannon LaPoint, Yueyang Shen, Ruoxi Guo, Jacqueline Alicea, et al. (2026). Trends in Adverse Event Monitoring and Reporting in Intervention Research with Young Autistic Children: A Project AIM Systematic Review. CRD/PROSPERO. Boston College.

Date de publication
11/06/2026
Identifiant
CRD420261384657
Auteurs
Kristen Bottema-Beutel, Micheal Sandbank, Tiffany Woynaroski, Jacob Feldman, Shannon LaPoint, Yueyang Shen, Ruoxi Guo, Jacqueline Alicea, Samantha Brayton
Source
CRD/PROSPERO
Type de référence
systematic_review_registry
Éditeur
Boston College
Source de métadonnées
crd.york.ac.uk

Résumé

Our objectives are to update analyses reported in earlier versions of Project AIM: (a) the proportion of studies that mention adverse events, and (b) quantities of each type of adverse event. We then sought to explore new aspects of adverse event monitoring and reporting: (c) what proportion of studies provide adverse event monitoring protocol details, including whether monitoring was active, passive, or both; procedures for distinguishing between adverse events and adverse effects; procedures for distinguishing between adverse events and severe/serious adverse events; and procedures for assessing harms (i.e., adverse events after the intervention period is over); (d) what proportion of studies interpret adverse events in the discussion and/or conclusion of their studies; (e) what proportion of studies mention adverse events and provide protocol descriptions by intervention type. We also aim to determine (f) trends over time in reporting adverse events and describing monitoring protocols.